An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2 is a research paper published in EMBO Molecular Medicine (2022). On theSindex it has a DataRank of 0. It has been cited 53 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
HHS ¦ NIH ¦ National Heart, Lung, and Blood Institute
Grant: R01‐HL162308
HHS ¦ NIH ¦ National Heart, Lung, and Blood Institute
Grant: R01HL157489
HHS ¦ NIH ¦ National Institute of Allergy and Infectious Diseases
Grant: R43‐AI162329
NHLBI NIH HHS
Grant: R01 HL163978
NIAID NIH HHS
Grant: R43 AI162329
NHLBI NIH HHS
Grant: R01 HL162308
National Institutes of Health
Grant: 6R43AI162329-02
Optimization of a broad and potent decoy receptor for SARS-associated viruses
National Institutes of Health
Grant: 1R01HL162308-01
Mechanisms and Treatment of SARS-CoV-2 induced Lung Endothelial Injury
National Institutes of Health
Grant: 7R01HL157489-03
Endothelial antigen presentation to T cells as a pathogenic mechanism in influenza-induced acute lung injury
FWCI
4.93
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals